-
公开(公告)号:EP1675861A1
公开(公告)日:2006-07-05
申请号:EP04768197.8
申请日:2004-08-26
申请人: Vernalis (Cambridge) Limited , Cancer Research Technology Limited , The Institute of Cancer Research
发明人: DYMOCK, Brian William, Evotec OAI Ltd , DRYSDALE, Martin James, Vernalis (Cambridge) Ltd , FROMONT, Christofe, Vernalis (Cambridge) Ltd , JORDAN, Allan, Vernalis (Cambridge) Limited , BARRIL-ALONSO, Xavier
IPC分类号: C07D495/04 , A61K31/00 , A61P35/00
CPC分类号: C07D495/04 , A61K31/519
摘要: Compounds of formula (1) are inhibitors of HSP90 activity in vitro or in vivo, and of use in the treatment of inter alia, cancer: wherein R2 is a group of formula -(Ar1)m-(Alk1)P-(Z)r-(Alk2)S-Q wherein Ar1 is an optionally substituted aryl or heteroaryl radical, Alk' and Alk 2 are optionally substituted divalent C1-C3 alkylene or C2-C3 alkenylene radicals, m, p, r and s are independently 0 or 1, Z is -0-, -S-, -(C=O)-, -(C=S)-, -S02-, -C(=O)O-, -C(=O) NR A- , -C(=S)NR A-, -S02NR A-, -NR AC(=O)_, -NR AS02- or-NR A-wherein R A is hydrogen or C1-C6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R3 is hydrogen, an optional substituent, or an optionally substituted (C1-C6)alkyl, aryl or heteroaryl radical; and R4 is a carboxylic ester, carboxamide or sulfonamide group.
摘要翻译: 式(1)化合物是体外或体内HSP90活性抑制剂,特别是用于治疗癌症:其中R2是式 - (Ar1)m-(Alk1)P-(Z) (Alk2)SQ其中Ar1是任选取代的芳基或杂芳基,Alk'和Alk2是任选取代的二价C1-C3亚烷基或C2-C3亚烯基,m,p,r和s独立地是0或1, (O)O - , - C(= O)NR A - , - (C = (= S)NR A - , - SO 2 NR A - , - NR AC(= O) - ,-NR ASO 2 - 或-NR A - ,其中RA是氢或C 1 -C 6烷基,并且Q是氢或任选 取代的碳环或杂环基团; R3是氢,任选的取代基或任选取代的(C1-C6)烷基,芳基或杂芳基; R4是羧酸酯,羧酰胺或磺酰胺基团。
-
公开(公告)号:EP1675861B1
公开(公告)日:2015-12-23
申请号:EP04768197.8
申请日:2004-08-26
发明人: DYMOCK, Brian William, Evotec OAI Ltd , DRYSDALE, Martin James, Vernalis (Cambridge) Ltd , FROMONT, Christofe, Vernalis (Cambridge) Ltd , JORDAN, Allan, Vernalis (Cambridge) Limited , BARRIL-ALONSO, Xavier
IPC分类号: C07D495/04 , A61K31/00 , A61P35/00
CPC分类号: C07D495/04 , A61K31/519
-